<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Orasure Technologies Inc — News on 6ix</title>
<link>https://6ix.com/company/orasure-technologies-inc</link>
<description>Latest news and press releases for Orasure Technologies Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/orasure-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a76678dffbe2df10bef0.webp</url>
<title>Orasure Technologies Inc</title>
<link>https://6ix.com/company/orasure-technologies-inc</link>
</image>
<item>
<title>OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-to-announce-first-quarter-2026-financial-results-and-host-earnings-call-on-may-6th</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-to-announce-first-quarter-2026-financial-results-and-host-earnings-call-on-may-6th</guid>
<pubDate>Wed, 22 Apr 2026 20:10:00 GMT</pubDate>
<description>BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at</description>
</item>
<item>
<title>OraSure Technologies Appoints John D. Bertrand to its Board of Directors</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-appoints-john-d-bertrand-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-appoints-john-d-bertrand-to-its-board-of-directors</guid>
<pubDate>Fri, 17 Apr 2026 00:10:00 GMT</pubDate>
<description>Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D. Bertrand to its Board of Directors as an independent director, effective immediately. Mr. Bertrand is a healthcare techn</description>
</item>
<item>
<title>Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/altai-capital-management-issues-letter-to-orasure-board-outlining-five-pillar-case-for-change-in-response-to-significant-and-continued-underperformance</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/altai-capital-management-issues-letter-to-orasure-board-outlining-five-pillar-case-for-change-in-response-to-significant-and-continued-underperformance</guid>
<pubDate>Tue, 17 Mar 2026 13:15:00 GMT</pubDate>
<description>LOS ANGELES, March 17, 2026--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors.</description>
</item>
<item>
<title>OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-highlights-significant-operational-progress-and-value-creation-initiatives-following-letter-from-altai-capital</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-highlights-significant-operational-progress-and-value-creation-initiatives-following-letter-from-altai-capital</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive</description>
</item>
<item>
<title>OraSure Announces Fourth Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-fourth-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-fourth-quarter-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended December 31, 2025. “Our Q4 results were consistent with our expectations, and revenue of $26.8 million was above the midpoint of our guidance range,” said Carrie Eglinton Manner, President and CEO of OTI. “We supported our customers in navigating a challeng</description>
</item>
<item>
<title>OraSure to Launch OraQuick™ HIV Self-Test in Canada</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-launch-oraquick-hiv-self-130500112</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-launch-oraquick-hiv-self-130500112</guid>
<pubDate>Tue, 10 Feb 2026 13:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada. The OraQuick™ HIV Self-Test is a point-of-care rapid antibody test. It is Canada’s first oral HIV self-test and detects antibodies for both HIV-1 and HIV-2, enabling individuals to find out their HIV statu</description>
</item>
<item>
<title>OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-fourth-quarter-2025-211500896</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-fourth-quarter-2025-211500896</guid>
<pubDate>Mon, 09 Feb 2026 21:15:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and acc</description>
</item>
<item>
<title>OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-confirms-receipt-director-180000072</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-confirms-receipt-director-180000072</guid>
<pubDate>Thu, 15 Jan 2026 18:00:00 GMT</pubDate>
<description>No Shareholder Action Required at This TimeBETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund’s founder Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders. As previously announced,</description>
</item>
<item>
<title>Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/altai-capital-management-nominates-two-133000440</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/altai-capital-management-nominates-two-133000440</guid>
<pubDate>Thu, 15 Jan 2026 13:30:00 GMT</pubDate>
<description>LOS ANGELES, January 15, 2026--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the "Board") at the 2026 Annua</description>
</item>
<item>
<title>OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-submits-ct-ng-molecular-130000314</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-submits-ct-ng-molecular-130000314</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Jan. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) (“OraSure” and “OTI”), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that it submitted two separate applications at the end of 2025 to the U.S. Food and Drug Administration (FDA) for clearance of its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) as well as its Colli-Pee™ at-home urine collection device for sexua</description>
</item>
<item>
<title>OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-issues-statement-regarding-182300779</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-issues-statement-regarding-182300779</guid>
<pubDate>Wed, 17 Dec 2025 18:23:00 GMT</pubDate>
<description>No Shareholder Action Required at This TimeBETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund’s founder, Rishi Bajaj, to stand for election to the Company’s Board of Directors (the “Board”) at its 2026 Annual Meeting of</description>
</item>
<item>
<title>OraSure to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-participate-upcoming-investor-conference-124500121</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-participate-upcoming-investor-conference-124500121</guid>
<pubDate>Mon, 17 Nov 2025 12:45:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 19, with a Q&A session scheduled for 10 a.m. CT A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. About OraSure Technologies,</description>
</item>
<item>
<title>OraSure Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-third-quarter-2025-210500106</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-third-quarter-2025-210500106</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. “In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to retur</description>
</item>
<item>
<title>OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-third-quarter-2025-113000015</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-third-quarter-2025-113000015</guid>
<pubDate>Wed, 29 Oct 2025 11:30:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and acces</description>
</item>
<item>
<title>OraSure Technologies Appoints Steven K. Boyd to its Board of Directors</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-appoints-steven-k-202200044</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-technologies-appoints-steven-k-202200044</guid>
<pubDate>Tue, 28 Oct 2025 20:22:00 GMT</pubDate>
<description>Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solut</description>
</item>
<item>
<title>OraSure Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-second-quarter-2025-200500993</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-second-quarter-2025-200500993</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also st</description>
</item>
<item>
<title>OraSure Appoints Anne Messing as Chief Commercial Officer</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-appoints-anne-messing-chief-110500816</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-appoints-anne-messing-chief-110500816</guid>
<pubDate>Mon, 04 Aug 2025 11:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building</description>
</item>
<item>
<title>OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-second-quarter-2025-200500914</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announce-second-quarter-2025-200500914</guid>
<pubDate>Mon, 21 Jul 2025 20:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access</description>
</item>
<item>
<title>OraSure Launches Novel Blood Collection Device for Proteomic Research</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-launches-novel-blood-collection-110500961</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-launches-novel-blood-collection-110500961</guid>
<pubDate>Thu, 10 Jul 2025 11:05:00 GMT</pubDate>
<description>The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for researchBETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an</description>
</item>
<item>
<title>OraSure Announces First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-first-quarter-2025-200500651</link>
<guid isPermaLink="true">https://6ix.com/company/orasure-technologies-inc/news/orasure-announces-first-quarter-2025-200500651</guid>
<pubDate>Wed, 07 May 2025 20:05:00 GMT</pubDate>
<description>BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. “Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related</description>
</item>
</channel>
</rss>